Strategic partnerships Leverage recent collaborations such as the Azra AI partnership and the Riverain Technologies integration to position RevealDx as a collaborative platform that integrates with complementary imaging tools, creating joint value propositions for health systems seeking end-to-end diagnostic workflows.

Clinical adoption Target mid to large healthcare networks and integrated delivery networks (IDNs) like TriHealth to expand adoption of RevealAI-Lung for standardized lung nodule assessment, leveraging their MDR certification status to accelerate deployment in compliant environments.

Regulatory leverage Emphasize the CE mark, UK MHRA registration, Health Canada, and TGA licensing to enterprise buyers seeking compliant AI lung cancer decision support, and tailor pilots in regions where regulatory clearance is a market differentiator.

Financing momentum Capitalize on the recent funding activity and notable investment rounds to engage potential customers with funded pilots or value-based pricing discussions, demonstrating financial credibility and faster ROI through improved diagnostic accuracy.

Market positioning Differentiate from competitors by highlighting radiomics and AI-enabled decision support capabilities, the patent position, and a growing partner ecosystem, while targeting health systems seeking innovative diagnostic pathways and data-driven outcomes.